๐Ÿ”” THIS WEBSITE IS FOR SALE โ€” Tools-Based Health Information Site with Great Profit Potential. Contact contact@thelungcancercure.com

The Lung Cancer Research Progress Tracker

A free, live dashboard of publicly available lung cancer research data โ€” how many active clinical trials exist right now, by treatment category, plus the FDA approval pace and survival-rate trends behind them. This tool tracks the state of the research effort. It is not a cure, a diagnosis tool, or medical advice.

โ€”
Active U.S. lung cancer trials tracked live via ClinicalTrials.gov
6
Major research categories monitored on this page
โ€”
Data as of
in ๐• r ๐Ÿ“Œ Click Here to Bookmark This Site

Live Research Momentum by Treatment Category

Each score below reflects how many currently active, publicly registered U.S. clinical trials fall into that treatment category, normalized on a 0โ€“100 scale relative to the largest category today. A higher score means more concurrent trial activity โ€” not a better outcome for any individual patient. Loading live data from ClinicalTrials.govโ€ฆ

Fetching current trial countsโ€ฆ

Data sources: Live trial counts are queried directly from the ClinicalTrials.gov public API (U.S. National Library of Medicine) at the moment you load this page. If the live query is unavailable, a cached reference dataset is shown instead and clearly labeled as such. This tool does not access, store, or transmit any personal or health information about you โ€” it only queries public, de-identified trial registry data.

Advertisement

Why This Matters: The Research Effort in Numbers

Lung cancer remains the leading cause of cancer death worldwide, and in the United States it is projected to cause more than 125,000 deaths in 2026 — more than colorectal, breast, and prostate cancer combined. Five-year survival for lung cancer caught at the earliest, localized stage is dramatically higher than for cancer discovered after it has spread, which is why early detection remains one of the largest single levers on outcomes. Since the mid-2010s, the pace of new lung cancer drug approvals has accelerated substantially, driven largely by two parallel research tracks: immunotherapy (drugs that help a patient's own immune system recognize cancer cells) and targeted therapy (drugs built around a specific genetic mutation driving a given tumor). Explore our full article library for plain-language explainers on how each of these treatment classes works, or visit the news section for ongoing coverage of individual trial results as they are published.

Frequently Asked Questions

Is there a cure for lung cancer?

There is currently no single cure for lung cancer. Outcomes vary significantly by stage at diagnosis, cancer subtype, and biomarker profile. Treatable and, in early-stage cases, curable outcomes do occur, particularly when the disease is caught before it spreads. This site tracks the volume and pace of public research aimed at improving those odds; it does not sell or claim a cure.

How many active lung cancer clinical trials are there right now?

The number changes continuously. This page queries ClinicalTrials.gov's public database live, in your browser, and displays the current total alongside a breakdown by treatment category.

What data does the Research Progress Tracker use?

The public ClinicalTrials.gov API (U.S. National Library of Medicine) for live trial counts, and publicly published FDA approval history and NCI SEER survival statistics for historical trend context.

Is this website medical advice?

No. This site is strictly informational. It does not diagnose, treat, or recommend any treatment, and does not match individuals to specific clinical trials. Always consult a licensed physician or oncologist about your own medical situation.

Advertisement

50 Facts About the State of Lung Cancer Research

This panel auto-advances every few seconds and cycles continuously through all 50 facts. Every fact links back to sourced context in our article library and news section.

Get New Research Findings by Email

Once a week, we summarize the most significant lung cancer research developments โ€” new trial results, FDA actions, and screening guidance changes โ€” in plain language. Free. No spam. Unsubscribe anytime.

By subscribing you agree to our Privacy Policy. We never sell your email address.